Preventing Errors with COVID-19 Vaccines: Learning from Vaccine Incidents

Strategies for Safe COVID-19 Vaccination
(see Table 1)

• Storage: Be ready to respond to temperature excursions (e.g., refrigerator failure) to prevent wastage.
• Preparation: Provide a quick-reference sheet at the point of dose preparation, and label all prefilled syringes.
• Administration: Use a checklist to identify vaccine contraindications or precautions.
• Documentation: Provide patients with documentation of vaccination. MyMedRec and CanImmunize apps are options to store this information.

This bulletin shares a number of leading practices that facilitate the safe administration of a COVID-19 vaccine. These practices, which incorporate learning from past vaccine errors, will evolve over time, as additional knowledge is gained and new guidance is developed.

In Canada, as of Feb. 25, 2021, Health Canada has approved 2 COVID-19 vaccines (known by the names of their manufacturers: Moderna and Pfizer-BioNTech), both of which use mRNA technology. Several vaccines using different technology (e.g., viral vector) are under consideration for approval.

LEARNING FROM VACCINE ERRORS

Two groups of vaccine errors were reviewed for this bulletin: worldwide incidents reported thus far involving COVID-19 vaccines and errors that have occurred in Canada with other vaccines. The latter were identified from a multi-incident analysis of more than 1300 vaccine errors reported to 3 ISMP Canada databases and CIHI’s National System for Incident Reporting database through December 2020. The risks and learning are categorized by 4 medication-use stages below and summarized in Table 1.

Storage

Each COVID-19 vaccine has distinct storage requirements, and all vaccines approved so far require storage in a refrigerator, a freezer, or an ultra-low-temperature freezer. An interruption in the cold chain could result in product spoilage. For example, several incidents have been traced to inadequate equipment for monitoring the temperature of freezers and refrigerators and/or the lack of a plan to deal with temperature excursions. To limit potential wastage of vaccine, process checks must be in place to ensure that public health guidance, as well as manufacturers’ temperature storage requirements, is followed.
Vaccine storage, whether in a refrigerator or a freezer, must be carefully scrutinized to ensure that products are appropriately segregated. Errors involving selection of the wrong product have occurred when refrigerators were poorly organized. For example, there have been instances when insulin or a neuromuscular blocker or another vaccine was administered instead of the intended vaccine product. In all of these incidents, a key contributing factor was storage of multiple products in close proximity. Ideally, bar-coding will be used during the vaccine selection step, as well as during preparation and administration.

The Pfizer-BioNtech product requires dilution after thawing, but the diluent is not supplied with the product and must be sourced separately. Inoculation of undiluted vaccine has been reported. Bundling the diluent vial with the vaccine vial when the latter is removed from the freezer provides workflow support to help prevent errors.

**Preparation**

Develop a standardized process for preparing doses and provide a quick-reference sheet at the point of dose preparation. Errors related to vaccine preparation include withdrawal and administration of the contents of an entire multidose vial to a single patient, needle-syringe misconnection, preparation of an incorrect volume, as well as inadequate or no dilution and administration of diluent only. To prevent preparation errors, United States Pharmacopeia (USP) has developed a COVID-19 Vaccine Handling Toolkit highlighting a number of operational considerations.

As part of the standardized process, labelling of prefilled syringes is essential, because it provides an opportunity for an extra check before dose administration. The syringe label should specify the name of the product (and its manufacturer), the dose (volume) for injection, the lot number, and the beyond-use date and time (i.e., the last date and time of day when the product can be used). It is also important to label any opened, partially used vials with both the puncture and beyond-use dates and times.

**Administration**

The person administering the vaccine should be alert to visual cues indicating a potential undetected error from a previous step (e.g., appearance of syringe contents differing from expectations, incorrect volume). Injection of an incorrect volume for multiple patients has been reported. Review of a labelled syringe prior to administration supports the identification of a potential error.

Before administration of a COVID-19 vaccine, each patient should be screened for contraindications or reasons that would affect their suitability for vaccination. For example, current guidelines advise separating administration of the COVID-19 vaccine by 14-28 days from most other vaccine products (e.g., shingles vaccine). If possible, the timing of future inoculations with a COVID-19 and other planned vaccines needs to be considered.

Shoulder injury related to vaccine administration, also known as SIRVA, is a well-established preventable adverse effect resulting from improper landmarking technique (Figure 1). It is easier for
those administering the vaccine to identify the correct injection site if the patient’s upper arm is bare. Accordingly, patients should be advised to wear suitable clothing (i.e., sleeveless/short-sleeved tops) to their appointment. In addition, vaccine stations should be set up to allow privacy.

**Documentation**

The currently available COVID-19 vaccines require 2 doses for maximum efficacy; there is a risk that the wrong product could be used for the second dose. At the time of publication, the National Advisory Committee on Immunization (NACI) is recommending that the vaccine series for each person be completed with the same COVID-19 vaccine; however, NACI also acknowledges that if the same product is not available at the time of the second dose, a vaccine of similar type (e.g., another mRNA product, if the first dose was an mRNA product) can be used.16

Documentation also supports the prevention of scheduling errors. Each of the currently approved vaccines has its own recommended interval between the 2 required doses. Information about the COVID-19 vaccines provided by Health Canada and NACI16 includes information about the timing of COVID-19 vaccine doses, as well as the timing of these doses in relation to administration of other vaccine products.

Booking a patient’s second appointment at the time of the first visit will support vaccination at the right time, when possible. There has been a report describing a scheduling error due to miscommunication.13 Follow-up by phone, text, or email is recommended to ensure patients receive the second dose on time.18

**CONCLUSION**

Knowledge about the appropriate use and safety of COVID-19 vaccines will continue to evolve, and guidance from health authorities, such as Health Canada, NACI, public health organizations, and provincial/territorial health ministries, will be updated regularly.

Vaccine-related adverse drug reactions should be reported through the customary reporting channels. In addition, consider documenting vaccine errors (regardless of outcome) through an organization’s usual reporting process and/or ISMP Canada’s Individual Practitioner Reporting program. These reports will support future learning and error prevention.

Providing patients with documentation of vaccination can prevent errors. When patients presenting for their second dose do not know which product they received initially, such documentation can be used to confirm or identify the correct vaccine to be administered. Patients can also be encouraged to take a picture of the documentation or to enter it into a medication app such as MyMedRec or CanImmunize.
### Table 1: Strategies for Safe Immunization with COVID-19 Vaccines

<table>
<thead>
<tr>
<th>Vaccine Use Stage</th>
<th>Risk for COVID-19 Vaccine Error</th>
<th>Strategies for Safe Vaccine Practices</th>
</tr>
</thead>
</table>
| **Storage**       | • Interruption of the cold chain, resulting in product spoilage  
               • Poor organization of storage areas, leading to selection of the wrong product  
               • Administration of undiluted vaccine  
               • Selection of outdated (expired) product | ✓ Follow the manufacturer’s storage instructions and public health guidelines for temperature monitoring, and develop a preparedness plan for temperature excursions.  
               ✓ Never store different vaccines or drug products in one container and clearly separate and label products; consider a dedicated refrigerator/freezer.  
               ✓ Wherever possible, use bar-coding technology for product identification.  
               ✓ Consider bundling any required diluent together with the vaccine (e.g., upon removal of the vaccine from the freezer).  
               ✓ Regularly review refrigerated/frozen vaccines, and remove any expired product. |
| **Preparation**   | • Improper or no dilution of vaccines that require dilution (e.g., Pfizer-BioNTech product)  
               • Use of product past its beyond-use date and time | ✓ Develop and follow a standard process, supported by a real-time, quick-reference sheet for dose preparation of each vaccine product.  
               ✓ Label all prefilled syringes with the product name, dose (volume), lot number, and beyond-use date and time.  
               ✓ Label all vaccine vials with both the puncture and beyond-use date and time.  
               ✓ Wherever possible, use bar-coding technology for product identification. |
| **Administration**| • Providing a vaccine when contraindicated  
               • Poor administration technique | ✓ Use a checklist to identify vaccine contraindications or precautions.  
               ✓ Use appropriate landmarking to avoid injection complications.  
               ✓ Suggest that patients wear short-sleeved or sleeveless clothing to their vaccine appointments. |
| **Documentation** | • Poor documentation of vaccination, or absence of documentation  
               • Poor communication related to scheduling of vaccine doses | ✓ Provide patients with documentation of vaccination, including product name, lot number, and date of vaccination. MyMedRec and CanImmunize apps are options to store this information (including pictures).  
               ✓ During the first vaccine appointment, book the patient’s second appointment (at an appropriate interval), if possible. Send appointment reminders by phone, text, or email. |
LEARNING FROM VACCINE ERRORS


17. Bancsi A, Houle SKD, Grindrod KA. Getting it in the right spot: shoulder injury related to vaccine administration (SIRA) and other injection site events. Can Pharm J. 2018;151(5):295-299.


REFERENCES


February 2021 - Newsletter:  
**Consumer Tips to Prevent COVID-19 Vaccine Errors**

A recent SafeMedicationUse.ca newsletter shared tips with consumers to help them safely receive a COVID-19 vaccine. With the continuing evolution of vaccine guidance, as reported and widely discussed in the media, consumers may have questions about whether the vaccine is safe for them. For example, organizations like the Society of Obstetricians and Gynaecologists of Canada are advocating that pregnant individuals have the opportunity to receive a COVID-19 vaccine, if the benefits of receiving the vaccine outweigh the risks. The newsletter also describes how consumers can help to prevent errors.

Read the newsletter at: https://safemedicationuse.ca/newsletter/COVID-19-vaccine.html

---

**Report Medication Incidents**  
(Including near misses)

**Online:** www.ismp-canada.org/err_index.htm  
**Phone:** 1-866-544-7672

ISMP Canada strives to ensure confidentiality and security of information received, and respects the wishes of the reporter as to the level of detail to be included in publications. Medication Safety bulletins contribute to Global Patient Safety Alerts.

**Stay Informed**

To receive ISMP Canada Safety Bulletins and Newsletters visit:  
www.ismp-canada.org/stayinformed/

This bulletin shares information about safe medication practices, is noncommercial, and is therefore exempt from Canadian anti-spam legislation.

**Contact Us**

**Email:** cmirps@ismpcanada.ca  
**Phone:** 1-866-544-7672

©2021 Institute for Safe Medication Practices Canada.